Published in final edited form as:

Semin Cancer Biol. 2016 June ; 37-38: 26–35. doi:10.1016/j.semcancer.2015.12.005.

Systemic DNA damage responses in aging and diseases

Flavia Ribezzo¹, Yosef Shiloh², and Björn Schumacher^{1,*}

¹Institute for Genome Stability in Ageing and Disease, Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases (CECAD) Research Center, Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany

²The David and Inez Myers Laboratory for Genetic Research, Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

Abstract

The genome is constantly attacked by a variety of genotoxic insults. The causal role for DNA damage in aging and cancer is exemplified by genetic defects in DNA repair that underlie a broad spectrum of acute and chronic human disorders that are characterized by developmental abnormalities, premature aging, and cancer predisposition. The disease symptoms are typically tissue-specific with uncertain genotype-phenotype correlation. The cellular DNA damage response (DDR) has been extensively investigated ever since yeast geneticists discovered DNA damage checkpoint mechanisms, several decades ago. In recent years, it has become apparent that not only cell-autonomous but also systemic DNA damage responses determine the outcome of genome instability in organisms. Understanding the mechanisms of non-cell-autonomous DNA damage responses will provide important new insights into the role of genome instability in human aging and a host of diseases including cancer and might better explain the complex phenotypes caused by genome instability.

The cellular DNA damage response (DDR)

The genetic information is constantly threatened by a plethora of genotoxic attacks. DNA damage can be caused by a variety of exogenous or endogenous agents. The first are environmental agents such as ultraviolet (UV) light, ionizing radiation (IR), as well as many genotoxic chemicals. The latter are by-products of cellular metabolic circuits such as oxidative respiration or events such as lipid peroxidation, which give rise to reactive oxidative species (ROS). In addition, spontaneous events constantly challenge the stability of DNA chemical bonds[1]. Depending on the source of damage, DNA can be affected in different ways, varying from single-strand breaks (SSBs), abasic sites and modified bases to highly toxic lesions such as small or bulky adducts and lesions, interstrand crosslinks (ICLs) and double-strand breaks (DSBs) (Figure 1). Lesions might compromise DNA metabolism by interrupting replication or transcription. It is thought that DNA damage accumulation with aging results in loss of cellular functionality and ultimately degeneration of cells and tissues. Erroneous repair, however, can lead to mutations and chromosomal aberrations,

*Correspondence: bjoern.schumacher@uni-koeln.de.

The authors declare no competing interests.

which when affecting tumor suppressor genes, drive carcinogenesis. Alternatively, unrepaired DNA lesions can lead to cell malfunction or cell senescence and eventually cell death. Importantly, DNA damage compromises regenerative capacities of stem cells and disturbs tissue integrity ultimately driving multiple pathologies during the aging process. It is thus essential for the organism to preserve the stability and integrity of its genome.

The sophisticated machineries that respond to DNA damage are highly conserved throughout evolution. In addition to complex DNA repair pathways, special DNA damage-induced checkpoints temporarily halt cell cycle progression providing a time window for the cell to repair the lesions. The unscheduled cell cycle arrest in turn is associated with modulation of many of the cell's physiological circuits. Thus, the cellular response to DNA damage called 'the DNA damage response' (DDR) turned out to be a vast signaling network encompassing the repair mechanisms and numerous signaling pathways, presenting one of the most comprehensive cellular responses to a stimulus.

Defective DDR and human disease

The relationship between genome stability and human health is illustrated by the genome instability syndromes, typically characterized by progressive degeneration of specific tissues, cancer predisposition, chromosomal instability, and hypersensitivity to DNA damaging agents[2,3]. The large variety of damage types requires specialized repair machineries. Mismatch repair (MMR) corrects errors that stem from mismatches that occurred during DNA replication, base excision repair (BER) removes small chemical alterations of bases, which could miscode and therefore result in mutagenesis. More complex damage types such as bulky lesions are resolved by nucleotide excision repair (NER), while homologous recombination and non-homologous end joining (HR and NHEJ) repair DSBs, and an elaborate enzymatic cascade repairs SSBs. The highly toxic ICLs are removed in a complex repair reaction involving the Fanconi anemia (FA) proteins[4]. While each of those repair systems is of paramount importance for human health, we will here focus on the consequences of dysfunctional NER and aberrant responses to DSBs to exemplify cell-autonomous and systemic DNA damage responses and their role in disease.

Complex consequences of DNA repair deficiencies in human disease: Distinct outcomes of defects in Nucleotide excision repair (NER) in development, aging, and cancer

Nucleotide excision repair deals primarily with helix-distorting DNA lesions such as UV-induced cyclobutane pyrimidine dimers (CPDs) and pyrimidine 6-4 pyrimidones (6-4PPs) that interfere with replication and transcription. These intrastrand dimers are resolved by removal of the damaged stretch of the strand and refilling of the gap by using the complementary strand as a template. The helix distortion is recognized by two different subpathways: global-genome NER (GG-NER) which scans the whole genome, and transcription-coupled NER (TC-NER) dealing with damage that blocks elongating transcription machineries. Defects in GG-NER give rise to the cancer-prone syndrome, xeroderma pigmentosum (XP). XP is characterized by pigmentation abnormalities, sun sensitivity, atrophic skin and most severely, leads to markedly elevated skin cancer. Mutations in one of seven genes (*XP-A to G*) that are involved in NER have been identified

in XP patients. In addition, XP can be caused by mutations in *XP-V*, which instead of functioning directly in NER encodes the DNA polymerase eta that can bypass UV-induced lesions thus instead of repairing tolerates lesions during replication. By contrast, TC-NER defects do not lead to cancer susceptibility but instead cause Cockayne syndrome (CS) that is characterized by severe growth and intellectual impairment and multiple manifestations of premature aging. Mutations in the genes *CSA* and *CSB* (CS complementation group A and B) have been identified in CS patients. Specific mutations in the same two genes can give also rise to the even more severe cerebro-oculo-facio-syndrome (COFS) or the mild UV-hypersensitivity syndrome [5] with uncertain genotype-phenotype correlations. Notably, different mutations in the same gene can lead to different pathologies; for example, mutation in the *XPB* gene can lead either to XP or trichothiodystrophy (TTD). TTD patients share many similarities to CS patients, but in addition display characteristic brittle hair and nails [6]. Moreover, mutated *XPB*, *XPB*, *XPF* and *XPG* can result not only in XP but also in a very rare XP-CS combination depending on the specific mutations. Genetic mouse models were generated to further investigate the disease mechanisms underlying the distinct NER syndromes. NER-deficient mice recapitulate the UV sensitivity and develop skin cancer upon low doses of UV irradiation. Mutations in single genes, such as *Csa* or *Csb*, however, do not result in overt disease phenotypes as in the human patients [7]. Only further abrogation of NER by ablation of genes such as *Xpc* or *Xpa* recapitulate the severe growth retardation and premature aging observed in CS patients [8]. Mutations in *Ercc1*, *Xpf* or *Xpg*, in contrast, are sufficient for triggering postnatal developmental failure and accelerated tissue degeneration [9,10].

Taken together, these syndromes have established that specific molecular defects in responding to DNA damage lead to distinct pathological outcomes: mutations that increase the mutation rate, such as GG-NER defects, elevate cancer risk, while defects that hamper transcription-coupled repair impair developmental growth and tissue functionality, ultimately accelerating the aging process. However, the human pathologies as well as the murine models also exemplify the vast complexity of physiological outcomes of alterations in the DNA metabolism. Importantly, the DNA repair defects and cellular sensitivities to genotoxic insults alone cannot entirely explain the pathologies and physiological alteration observed in the patients or animals models of NER deficiencies.

The cellular response to DNA double-strand breaks (DSBs)

The DDR is most vigorously activated by DSBs. Following induction by this highly cytotoxic DNA lesion, the DDR mounts up as a vast signaling network that activates not only DSB repair mechanisms but in addition sets in motion numerous pathways, which rapidly modulate many physiological processes [4,11–16]. DSBs can be induced by ionizing radiations, radiomimetic chemicals, or endogenous reactive oxygen species [17]. They also accompany physiological genomic transactions such as meiotic recombination [18,19] and the rearrangement of antigen receptor genes in the adaptive immune system [20]. DSBs are ultimately repaired via direct NHEJ or through HR-mediated recombination between sister DNA molecules. The NHEJ process can be divided into several subpathways [21–24]. HR is also involved in resolving replication fork breakdown and, together with the Fanconi proteins, removes interstrand crosslinks (ICLs). These lesions are challenging to repair as

both strands are damaged. HR is more accurate as it takes place in S and G2 phases of the cell cycle when the DNA is replicated and therefore a second copy of the sequence is available, whereas NHEJ occurs throughout the cell cycle including the G1 phase when no undamaged copy is present that could be used as a template.

However, DSB repair constitutes just one branch of the larger DSB response, which also activates special cell cycle checkpoints, modulates gene expression, alters protein turnover and activity, and affects many other cellular circuits. This extensive network is based on a group of *bona fide* DDR players, but it also turns to other arenas of cellular metabolism to temporarily recruit numerous players to the DDR where they undergo specific post-translational modifications (PTMs) [12,13,16,25–27]. The DSB response begins with *sensor/mediator* proteins which are rapidly recruited to the damaged DNA sites where they form large structures at nuclear foci[28] in a finely regulated manner [12,13]. While chromatin is reorganized around the break site and the DSB ends are processed in preparation for repair, a signal, whose physical identity is not entirely clear, is sent to the *transducers* – powerful protein kinases that subsequently relay the signal to numerous downstream *effectors* involved in a multitude of pathways.

Mutations that abrogate the DDR lead to complex diseases involving tissue degeneration, cancer susceptibility and accelerated aging

The primary transducer of the DSB response network is the protein kinase, ATM [14,16,29], and its activity is markedly enhanced in response to DSBs. Full and timely activation of ATM is dependent on the MRE11-RAD50-NBS1 (MRN) complex – a central DSB sensor[30,31]– and is accompanied by a flurry of PTMs on the ATM molecule, including several autophosphorylations and acetylations[14,16,32–36]. Activated ATM then phosphorylates numerous players in various pathways of the DSB response[16,36–39]. Among others, ATM phosphorylates checkpoint kinase 2 (CHK2), which is activated by this phosphorylation, and p53, which is activated and stabilized. Both are involved in the induction of senescence and apoptosis [40]. ATM's substrates include other protein kinases, which are activated via their ATM-mediated phosphorylation, and in turn phosphorylate their own targets. Hence, this phosphorylation network is multi-layered [39]. ATM also impacts tumor suppression through the senescence regulator ARF [41], which in turn impacts NF- κ B and p53 through the DDR kinases ATR and CHK1 [42]. It was recently proposed that ATM might be involved in many DNA repair pathways and other aspects of genome stability by virtue of its ability to phosphorylate key players in these pathways, in addition to its cardinal role as the mobilizer of the DSB response [43]. Thus, ATM probably tends to the daily wear and tear of the genome, beyond its response to DSBs.

While ATM's role in the DSB response is its most extensively studied function, ATM has recently emerged as a homeostatic protein kinase that is active in other stress responses and in several metabolic circuits[16,44,45]. Notable among them are redox balance [44,46], glucose and lipid metabolism, mitochondrial homeostasis and peroxisome-associated autophagy [16,44,45,47–51].

ATM belongs to a family of PI-3 kinase-like protein kinases (PIKKs) [52,53]. This family includes, among others, the catalytic subunit of the DNA-dependent protein kinase (DNA-

PKCs), which is involved in the NHEJ pathway of DSB repair and probably also in other genotoxic stress responses [54,55] and ATR, which responds primarily to stalled replication forks [11,56]. Evidence suggests a considerable degree of redundancy and collaboration between these three PIKKs, which preferably phosphorylate Ser or Thr residues followed by Gln (S/TQ motif) [11–13,53,57].

Prototypic genome instability syndromes resulting from defective response to DSBs are ataxia-telangiectasia (A-T) and Nijmegen breakage syndromes (NBS) [58]. A-T, which is caused by null mutations in the *ATM* gene, includes progressive neurodegeneration – primarily of the cerebellum, immunodeficiency, oculocutaneous dilated blood vessels (telangiectasia), cancer predisposition and acute sensitivity to ionizing radiation and other DSB-inducing agents [59]. NBS shares with A-T the immunodeficiency, cancer predisposition and extreme sensitivity to ionizing radiation (IR), but has distinct neurological manifestations - microcephaly and intellectual impairment [60]. NBS is caused by hypomorphic mutations in the *NBS1* gene, which encodes the NBS1 component of the MRN complex.

Also defects in repairing ICLs lead to cancer-susceptibility and segmental (i.e. tissue specific) progeroid features in FA patients. FA is manifested by pancytopenia, which is triggered by increased apoptosis in hematopoietic cells as well as leukemia resulting from high levels of chromosomal aberrations [61]. Therefore FA gives rise to both cancer and accelerated-aging phenotypes such as stem cell exhaustion. Mutations in genes encoding key players in SSB repair give rise to disorders involving primarily various patterns of neurodegeneration¹ [62]. Also mutations in several RecQ helicases cause syndromes that are characterized by cancer susceptibility and, due to the relatively late onset of the disorders, some of the most recognizable features of accelerated aging. Werner, Bloom, and Rotmund-Thomson syndromes are caused by mutations in the WRN, BLM, and REQL4 helicases that are important for genome maintenance during replication and recombination repair² [63]. In contrast, structural defects in the nuclear lamina result in progeroid features without markedly elevating the cancer risk in Hutchison-Gilford progeria syndrome (HGPS) or mandibuloacral dysplasia (MAD), which are caused by mutation in the *LMNA* or *ZMPSTE24* genes[64].

Recent evidence suggests that variation in DDR efficiency also contributes to a variety of metabolic diseases [65], and ATM was specifically implicated in critical metabolic circuits, such as redox balance, glucose and lipid metabolism, mitochondrial and peroxisomal homeostasis [16,45,47–50,66]. Notably, in mice, loss of one or two *Atm* alleles aggravates the metabolic syndrome of apoE-deficient animals [67–69], and murine *Atm* was implicated in regulation of adipocyte differentiation [48].

Taken together, defects in the DNA damage response machinery have provided insight into the complexity of the organism's systemic responses to DNA damage, which cannot be explained by cell-autonomous consequences of DNA damage alone. This is exemplified by the specificity of the phenotypes described above, as different mutations sometimes even in the same genome maintenance gene can lead to diverse disease features. The phenotypic complexity is also reflected in the pathologies in mouse disease models, some of which have

been engineered to carry the exact same disease causing mutations that are found in human patients.

Non-cell autonomous DNA damage responses

An important DDR factor that is activated by ATM in response to DSBs is the p53 protein. p53, once coined as the ‘guardian of the genome’, functions as a tumor suppressor protein by inducing transient cell cycle arrest, which can lead to cell senescence or cell death in response to DNA damage or oncogenic growth signaling [70]. Roughly half of all human tumors carry mutations in the *TP53* gene encoding p53. While loss of p53 function fuels aberrant cell proliferation and thus tumorigenesis, constitutive p53 activity can result in premature tissue degeneration as it prevents cell proliferation necessary for stem cell renewal and triggers aberrant apoptosis ultimately leading to tissue degeneration. The effects of increased activity of p53 were studied in mice that express a constitutively active *Tp53* alleles [71,72]. The animals exhibited reduced cancer frequencies but significant decrease in lifespan and signs of accelerated aging. Therefore, the balance of p53 levels and activity are critical in terms of cancer predisposition and in lifespan. Indeed, a “super-p53” mouse that carried an extra copy of p53 was more cancer protected than mice with only two copies of the p53 genes [73]. Addition of an extra copy of the gene encoding the tumor suppressor ARF (“super-Arf-super-p53” mouse) led to further protection from cancer and the mice outlived wild-type mice [74]. Intriguingly, p53 activity was shown not only to be a key factor in the DDR but also to have cell-non-autonomous consequences by promoting clearance of damaged cells through the activation of the innate immune system [75,76]. Indeed, the DDR also has non-cell autonomous consequences through the senescence-associated secretory phenotype (SASP) [77].

Aging, cell senescence and the DDR

It is becoming clear that individual differences in maintaining genome stability are responsible for a substantial part of the vast variation in aging and associated diseases [3,78–83]. This is vividly exemplified by the segmental (tissue-specific) accelerated aging observed in several genome instability syndromes in humans and mouse models of DNA repair deficiencies [3,84–86]. On the other hand, evidence mounts of the intimate connection between the organism’s aging and cell senescence. Cellular senescence, which can be induced by various stresses, has been implicated in development, wound healing, tissue repair and aging [87–92]. It is now well established that senescent cells accumulate during aging [77,80,88,91,93–95] and are involved in many age-related pathologies, including, ironically, cancer [88,90]. Strikingly, cell senescence may lead to different outcomes – suppression of malignancy or acceleration of aging – depending on the context and persistence of senescent cells *in vivo* [88,90,91]. Thus, cellular senescence is an example of the antagonistic pleiotropy theory that poses that processes that are beneficial early in life may be harmful later. We will in this context particularly focus on the non-cell-autonomous consequences of cellular senescence that have emerged in recent years.

The hallmark of cellular senescence is an irreversible arrest of cellular proliferation. The main pathways that lead to this cell cycle arrest are governed by two tumor suppressor axes:

the p53-p21 axis and the p16^{INK4a}-pRB axis. Importantly, rather than a finite, static end point, the senescent state is complex and dynamic due to a senescence-associated secretory phenotype (SASP) - the secretion, by senescent cells, of a suite of cytokines, growth factors and proteases that promote tissue repair and regeneration or inflammation [87,90,91]. The SASP is a plastic phenotype, and its composition varies with genotype, cell type and senescence stimulus. Chronic presence of senescent cells and a persistent SASP cause local and systemic inflammation, which fuels a variety of age-related diseases. Evidence for this has been obtained in a number of mouse models [90,92,96–98]. The role of cellular senescence in aging is particularly well illustrated in mice with defective BubR1 protein - a component of the mitotic checkpoint for spindle assembly [99]. These mice display multiple progeroid features and vastly elevated amounts of senescent cells. The causal role of cellular senescence in the progeroid phenotype of these animals was demonstrated by the addition of mutant p16^{INK4a} gene that abrogated the senescence program thus alleviating the pathology of the *BubR1* mutant mice [100]. Intriguingly, elimination of senescent cells in these mice by expressing a caspase-8 transgene under the control of a p16^{INK4a} promoter attenuated the aging phenotype [96]. Strikingly, these results suggested that clearance of senescent cells is sufficient to reverse age-related pathology.

SASP might also stimulate the growth of tumors, by secreting for example factors such as amphiregulin and growth-related oncogene (GRO) α and high levels of IL-6 and IL-8. For instance, it was observed in xenograft studies, that senescent fibroblasts stimulated progression and hyperproliferation of premalignant epithelial cells resulting in formation of xenograft tumours [101]. This stimulation was shown to be in part due to SASP factors released by senescent cells, particularly matrix metalloproteinases (MMPs) [102].

Among the most potent inducers of the SASP are genotoxic stresses and conditions that lead to persistent DNA damage signaling [103]. Indeed, several DDR players, including ATM, NBS1 and CHK2, are involved in establishing and maintaining the SASP [104]. Thus, the senescence response, and particularly the SASP, is a strong candidate for linking aging phenotypes and age-related rises in genotoxic stress [105,106]. The Janus face of SASP, with beneficial aspects as opposed to its role in detrimental inflammatory and degenerative events is further exemplified in recent findings suggesting the involvement of cell senescence in embryonic development. Senescent cells were found in many tissues throughout the embryo and in known signaling centers in embryonic patterning, including the apical ectodermal ridge (AER) and the neural roof plate [107,108]. Moreover, SASP was recently found to be involved in tissue repair and wound healing, by inducing myofibroblast differentiation through the secretion of a SASP factor, platelet-derived growth factor AA (PDGF-AA) [87]. Impairment in the wound healing process is generally observed in healthy older individuals [109]. SASP was suggested to play a role in repairing of wound tissue by preventing fibrosis. For instance, senescent hepatic stellate cells (HSCs) accumulate in damaged liver and prevent liver fibrosis by inducing collagen degradation and upregulation of secreted matrix metalloproteinases, which have fibrolytic activity [110]. It was also proposed that the matricellular protein CNN1, expressed during wound healing, induced fibroblasts into senescence and restricts fibrosis by upregulating antifibrotic genes [111].

DDR can thus play a health-promoting role mainly by suppressing tumorigenesis but also by cell-non-autonomously supporting wound healing and preventing fibrosis through the SASP. During embryogenesis growth cues secreted by senescent cells might support tissue development. In contrast, chronic DDR could trigger systemic inflammation and tissue degeneration. Particularly studies that elevated tumor suppressor gene dosage or eliminated senescent cells could promote health and might potentially support extended healthspan during aging.

Link between DNA damage and the innate immune system

Cell senescence is thought to also play a key role in inducing tissue degeneration in part mediated through chronic inflammation [77]. It is widely accepted that chronic inflammation is an important contributing factor in aging and aging-related diseases. This concept was strengthened by previous studies, which identified an elevated expression of inflammatory genes in progeroid and normal aged mice [112]. Moreover, studies in a NER-deficient mouse model with mutated *Ercc1* gene [83] identified a link between the unresolved DNA damage and lipodystrophy. This was mediated by a chronic auto-inflammatory response which responded to unrepaired DNA damage in an ATM-dependent manner [79]. At the systemic level, a remarkable link has been shown between DNA damage responses and activation of the immune system in order to promote the clearance of damaged cells. An important example is the activation of the ATM- NF- κ B essential modulator (NEMO; IKK) axis by DSBs. DNA damage cause activation of ATM mediated by the induction of DSBs and SUMOylation of NEMO. ATM is then mediating the phosphorylation of NEMO which leads to the cIAP1-dependent monoubiquitination of NEMO. This allows the translocation of ATM and NEMO to the cytoplasm where ELKs and TRAF6 are polyubiquitinated and NEMO is monoubiquitinated. This induces in turn the activation of IKK via TANK1. The activation of IKK leads to the phosphorylation of I κ B α which causes the polyubiquitination and degradation of I κ B α and the release of the active NF- κ B dimer [113]. In Hutchinson-Gilford progeria syndrome (HGPS) activation of ATM and NEMO resulted in an elevated secretion of inflammatory cytokines. Inhibition of NF- κ B signalling could attenuate progeroid features in HGPS as well as in progeroid *Ercc1* mutants mice, supporting the idea that inflammatory responses play a major role in the aging-associated pathologies [114,115]. Moreover the link between DDR and activation of immune responses has been demonstrated in cells that were exposed to viral infection or genomic instability, leading to the expression of ligands, major histocompatibility (MHC) class I-like cell surface ligands (MICA and RAET-1 families), which bind and activate the immune receptor NKG2D present on a variety of immune cells such as NK cells, γ/δ T cells, CD8⁺ T cells and NKT cells [116]. The ligand induction requires the DDR kinases ATM, ATR or Chk1: blocking ATM, ATR or Chk1 inhibits ligand induction. This was tested in several murine tumor cell lines and showed as a consequence a decrease in the RAE1 levels [117]. In addition, the DDR also activates the immune system through the activity of the interferon (IFN)- regulatory factor (IRF) family of transcription factors. In particular, IRF1 induces the expression of a variety of immune system genes. Interestingly, in response to genotoxic stress, IRF-1 expression is up-regulated in an ATM-dependent manner [118,119]. Moreover, another IRF factor, IRF3, is also involved in the activation of an innate immune response in response to DNA damage, and this process is mediated by type I IFN response

such as expression of IFN α and IFN β [116]. Cytosolic DNA sensing mechanism involve sensors such as DNA-dependent activator of IRFs (DAI), which binds dsDNA and activates in turn the TANK-binding kinase 1 (TBK1)-IRF3 to regulate type I IFN response as well as absent in melanoma (AIM2), which acts through the inflammasome pathway to promote the release of interleukin (IL)-1 β [79]. In order to activate the TBK1-IRF3 pathway, stimulator of IFN genes (STING) is necessary to accompany TBK1 to the endosomal compartments for the activation of IRF3/IRF7 [120,121]. Another important signaling pathway functioning upstream of STING is based on activation of cyclin-GMP-AMP (cGAMP) by direct cytosolic binding of DNA to cGMP-AMP synthase (cGAS). cGAMP has been shown to activate IRF3 by interaction with STING [122]. A recent study showed that DNA damage accumulation caused by ATM deficiency or by exogenous genotoxic stress triggers the activation of type I IFNs. This was demonstrated to prime the innate immune system for enhanced anti-viral and anti-bacterial responses. The induction in IFNs production is mediated through activation of the STING pathway [123]. Not only ATM but also p53 was demonstrated to impact components of the immune system when intercellular cell adhesion molecule-1 (ICAM-1) was demonstrated to be directly induced by p53 independently of NF- κ B signaling [124]. Remarkably, another recent study has identified an alternative regulator of senescence, GATA4, previously known as a regulator of development during embryogenesis. The activation of the GATA4-mediated senescence pathway is triggered through inhibition of autophagy. GATA4 can therefore induce cell cycle arrest and senescence as well as activation of NF- κ B contributing to the maintenance of the SASP. This novel pathway is dependent on ATM and ATR but independent of p53 and p16^{INK4a}. An increase of GATA4 levels during human aging and in normal aging mice was suggested to play a role in driving the aging-dependent inflammation [125]. Moreover NF- κ B signaling has also been implicated in the local UV response in the skin. NF- κ B signaling together with mitogen-activated protein kinase (MAPK) activation is triggered in response to UV-induced DNA lesions leading to a complex response, which includes both apoptosis and innate immune activation. The skin resident Langerhans immune cells, in contrast, migrate to the lymph nodes to mediate a systemic immune suppression that counteracts the inflammation at the site of UV injury of the skin [126].

The systemic role of an innate immune response that is triggered upon cell-type specific genome instability has recently been demonstrated in the nematode worm *Caenorhabditis elegans*. Adult worms are comprised of postmitotic somatic tissues and a germline, which is undergoing continuous mitotic and meiotic cell divisions. While the somatic tissues are highly radio-resistance, germ cells are sensitive to DNA damage. Conserved DNA damage checkpoints halt the cell cycle of mitotically dividing germ cells and trigger *C. elegans p53* (*cep-1*) mediated apoptosis in meiotic pachytene cells [97–99]. Interestingly, somatic tissues response to DNA damage in germ cells through a phenomenon named “germline DNA damage-induced systemic stress resistance” (GDISR) [127]. Endogenous and/or exogenous DNA damage triggers an innate immune response through the activation of extracellular signal-regulated kinases 1/2 (ERK1/2) MAPK homolog MPK-1 (mitogen-activated protein kinase-1). The putative secreted immune peptides lead to the activation of the ubiquitin-proteasome system (UPS) in somatic tissue, which then promotes somatic endurance to multiple forms of stress such as elevated temperature. Moreover, the study showed that a

similar response was triggered upon intestinal pathogen infection, which is mediated by the activation of p38 homolog PMK-1 (P38 MAP Kinase family-1) and also leads to systemic stress resistance [127].

Recent studies revealed numerous unexpected interactions between genome maintenance responses and DDR-mediated innate immune system. Thus, the DDR induces complex systemic responses that not only trigger tissue inflammation but also support tissue maintenance and repair (Figure 2).

The somatotrophic axis and genome instability: endocrine adjustments to DNA damage accumulation in aging

Despite the physiological differences between humans and mice, progeroid mouse models based on mutations in DDR genes can provide insights on how mammals respond to unrepaired DNA damage. The developmental growth defects observed in defective NER mutants *Ercc1*^{-/-}, *Csb*^{m/m}/*Xpa*^{-/-} and *Xpd*^{TTD}/*Xpa*^{-/-} were associated with a systemic suppression of the growth hormone/insulin-like growth factor 1 (GH/IGF-1) somatotrophic growth axis [8] [10,128]. This systemic response to genomic instability was not only observed in NER-deficient mice but also in other progeroid models, specifically in mice deficient of Sirtuin 6 - a chromatin-associated member of the sirtuin family of NAD-dependent protein deacetylases, with a role in BER- and animals deficient of Zmpste24 - a metalloprotease required for lamin A processing [129]. Insulin-like signaling (IIS) was the first genetic pathway demonstrated to regulate the lifespan of animals [130]. In mammals, growth hormone (GH), produced in the pituitary gland binds to the growth hormone receptor (GHR) present in the liver and also in other peripheral tissues, thereby inducing the synthesis of insulin-like growth factor 1 (IGF-1). This, in turn, promotes body growth due to its potent mitogenic effects [131]. Ames and Snell dwarf mice fail to develop the pituitary gland and are therefore unable to secrete GH, and this results in growth retardation and exceptional longevity [132]. Also *Ghr* knockout and overexpression of the IGF-1 antagonist Klotho and to a lesser extent heterozygosity of *Igf-1 receptor* phenocopied the extended longevity of the Ames and Snell dwarf mice [132–134]. A decrease in GH and IGF-1 has also been observed during normal aging in mice, rats, and humans. As the attenuation of somatotrophic axis leads to a longevity phenotype, it was suggested that dampening of somatotrophic axis exerts a protective role by promoting tissue maintenance at the cost of growth [135]. For instance this was observed in the *Igfr*^{+/-} heterozygous animals, where it was shown that attenuation of somatotrophic axis was linked to increased resistance to oxidative stress [133]. However, in progeroid animals, the attenuation of the somatotrophic axis in response to DNA damage accumulation is taking place very early in their life thus hampering their normal developmental growth. Indeed, IGF-1 injections into HGPS mouse models allowed the animals to overcome their developmental growth retardation [136].

The growth promoting function of the somatotrophic axis also supports the growth of tumor cells as IGF-1 is a potent mitogenic factor and most cancer cells are critically dependent of IGF-1R mediated signaling [137]. The dampening of the somatotrophic axis might thus suppress tumorigenesis in DNA repair defective animals as well as during aging. Indeed, Ames dwarf mice and the *Ghr* knockout mice showed a reduction in occurrence of fatal

neoplastic disorders [138,139]. Mechanistically, it was demonstrated that persistent DNA lesions that lead to stalling of transcription complexes and are the culprit in progeroid mice, such as *Ercc1*^{-/-}, *Csb*^{m/m}/*Xpa*^{-/-}, trigger the attenuation of the receptors of GH and IGF-1 leading to IGF-1 resistance and elevated oxidative stress resistance and thus defining instigating events in the shift from growth to somatic maintenance amid DNA damage accumulation with aging [140]. A recent study has discovered a similar mechanism in *C. elegans*, where it was shown that transcription-blocking lesions induce the attenuation of insulin/insulin-like signaling (IIS) leading to activation of the critical IIS effector, the FOXO transcription factor DAF-16 [141]. The longevity effect of the IIS pathway is highly conserved throughout organisms. For instance, in *C. elegans*, inhibition of IIS results in the doubling of the organism's lifespan. In the nematode, *daf-2* encodes the homolog of the IGF-1R and insulin receptor (IR) and a decrease in its activity as well as mutations in its downstream target PI3 kinase, *age-1*, were shown to induce an increase in the organism's lifespan [142,143]. Inhibition of IIS affects the nematode's lifespan by inducing changes in gene expression mediated by the activation of the FOXO transcription factor DAF-16, which upon IIS inactivation enters the nucleus and regulates the expression of a variety of stress-response genes [143]. Therefore, mutation in *daf-16* entirely reverts the longevity phenotype observed by blocking the IIS [144]. A direct link between DNA damage and IIS was identified in *C. elegans*: DAF-16/FOXO is activated upon transcription-blocking UV-induced lesions in somatic tissues. DAF-16 activity leads to elevated tolerance to DNA damage as it allows proceeding of developmental growth and the maintenance of tissues even when completely NER deficient animals are incapable of repairing the DNA lesions. The DNA damage response of DAF-16 is specified by the GATA transcription factor EGL-27 that by interacting with DAF-16 induces developmental growth genes. The capacity of DAF-16 to response to DNA damage, however, declines with aging ultimately rendering the animals defenseless against increasing damage loads. Intriguingly, the attenuation of IIS and the resulting activation of DAF-16 could counteract the detrimental effects of genome instability by elevating DNA damage tolerance leading to enhanced tissue maintenance and extended longevity [141] and might thus provide an interesting opportunity for future therapies that aim at preventing age-related pathologies despite the invariant accumulation of DNA damage with aging.

Concluding remarks

Intense research over the past decades has provided deep insights into the mechanisms of DNA repair and the cellular response mechanisms through which DDR facilitates the repair process and prevents tumorigenesis. Insights from human DDR disorders and a variety of model systems including *C. elegans*, *D. melanogaster* and mammalian disease models have recently disclosed new perspectives on the consequences of DDR on the systemic level. The mediators of those cell-non-autonomous DDR include endocrine adjustments and the secretory properties of senescent cells that impact a variety of processes including metabolism, immunity, regeneration and tissue maintenance. Further mechanistic insights emanating from research in various biological model systems will result in a better understanding of how genome instability impacts aging and age-related diseases.

Acknowledgements

FR received a fellowship from the Marie Curie FP7 ITN aDDress 316390. BS acknowledges funding from the Deutsche Forschungsgemeinschaft (CECAD, SFB 829, SFB 670, and KFO 286), the European Research Council (ERC Starting grant 260383), Marie Curie (FP7 ITN CodeAge 316354, aDDress 316390, MARRIAGE 316964), the German-Israeli Foundation for Scientific Research and Development (GIF 1104-68.11/2010), the Deutsche Krebshilfe (109453), and the Bundesministerium für Forschung und Bildung (Sybacol FKZ0315893A-B). Work in the laboratory of YS is funded by the A-T Children's Project, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Israel Cancer Research Fund, the Israel Science Foundation, the German-Israeli Foundation for Scientific Research and Development, and the A-T Ease Foundation. YS is a Research Professor of the Israel Cancer Research Fund.

References

1. Lindahl T. Instability and decay of the primary structure of DNA. *Nature*. 1993; 362:709–715. DOI: 10.1038/362709a0 [PubMed: 8469282]
2. O'Driscoll M. Diseases Associated with Defective Responses to DNA Damage. *Cold Spring Harbor Perspectives in Biology*. 2012; 4:a012773–a012773. DOI: 10.1101/cshperspect.a012773 [PubMed: 23209155]
3. Maynard S, Fang EF, Scheibye-Knudsen M, Croteau DL, Bohr VA. DNA Damage, DNA Repair, Aging, and Neurodegeneration. *Cold Spring Harb Perspect Med*. 2015; 5:a025130.doi: 10.1101/cshperspect.a025130 [PubMed: 26385091]
4. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. *Mol Cell*. 2010; 40:179–204. DOI: 10.1016/j.molcel.2010.09.019 [PubMed: 20965415]
5. Laugel V, Dalloz C, Durand M, Sauvanaud F, Kristensen U, Vincent MC, et al. Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. *Hum Mutat*. 2010; 31:113–126. DOI: 10.1002/humu.21154 [PubMed: 19894250]
6. Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. *Neuroscience*. 2007; 145:1388–1396. DOI: 10.1016/j.neuroscience.2006.12.020 [PubMed: 17276014]
7. van der Horst GT, van Steeg H, Berg RJ, van Gool AJ, de Wit J, Weeda G, et al. Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. *Cell*. 1997; 89:425–435. [PubMed: 9150142]
8. van der Pluijm I, Garinis GA, Brandt RM, Gorgels TG, Wijnhoven SW, Diderich KE, et al. Impaired genome maintenance suppresses the growth hormone–insulin-like growth factor 1 axis in mice with Cockayne syndrome. *PLoS Biol*. 2006; 5:e2. [PubMed: 17326724]
9. Harada YN, Shiomi N, Koike M, Ikawa M, Okabe M, Hirota S, et al. Postnatal growth failure, short life span, and early onset of cellular senescence and subsequent immortalization in mice lacking the xeroderma pigmentosum group G gene. *Mol Cell Biol*. 1999; 19:2366–2372. [PubMed: 10022922]
10. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. *Nature*. 2006; 444:1038–1043. [PubMed: 17183314]
11. Marechal A, Zou L. DNA Damage Sensing by the ATM and ATR Kinases. *Cold Spring Harbor Perspectives in Biology*. 2013; 5:a012716–a012716. DOI: 10.1101/cshperspect.a012716 [PubMed: 24003211]
12. Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography. *Mutation Research/Reviews in Mutation Research*. 2012; 751:158–246. DOI: 10.1016/j.mrrev.2012.06.002
13. Sirbu BM, Cortez D. DNA Damage Response: Three Levels of DNA Repair Regulation. *Cold Spring Harbor Perspectives in Biology*. 2013; 5:a012724–a012724. DOI: 10.1101/cshperspect.a012724 [PubMed: 23813586]
14. Bhatti S, Kozlov S, Farooqi AA, Naqi A, Lavin M, Khanna KK. ATM protein kinase: the linchpin of cellular defenses to stress. *Cell Mol Life Sci*. 2011; 68:2977–3006. DOI: 10.1007/s00018-011-0683-9 [PubMed: 21533982]

15. Stracker TH, Roig I, Knobel PA, Marjanovi M. The ATM signaling network in development and disease. *Front Genet.* 2013; 4doi: 10.3389/fgene.2013.00037
16. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat Rev Mol Cell Biol.* 2013; 14:197–210. DOI: 10.1038/nrm3546
17. Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. *Current Biology.* 2014; 24:R453–R462. DOI: 10.1016/j.cub.2014.03.034 [PubMed: 24845678]
18. Lange J, Pan J, Cole F, Thelen MP, Jasin M, Keeney S. ATM controls meiotic double-strand-break formation. *Nature.* 2011; 479:237–240. DOI: 10.1038/nature10508 [PubMed: 22002603]
19. Borde V, de Massy B. Programmed induction of DNA double strand breaks during meiosis: setting up communication between DNA and the chromosome structure. *Current Opinion in Genetics & Development.* 2013; 23:147–155. DOI: 10.1016/j.gde.2012.12.002 [PubMed: 23313097]
20. Alt FW, Zhang Y, Meng F-L, Guo C, Schwer B. Mechanisms of Programmed DNA Lesions and Genomic Instability in the Immune System. *Cell.* 2013; 152:417–429. DOI: 10.1016/j.cell.2013.01.007 [PubMed: 23374339]
21. Shibata A, Jeggo PA. DNA Double-strand Break Repair in a Cellular Context. *Clinical Oncology.* 2014; 26:243–249. DOI: 10.1016/j.clon.2014.02.004 [PubMed: 24630811]
22. Jasin M, Rothstein R. Repair of strand breaks by homologous recombination. *Cold Spring Harbor Perspectives in Biology.* 2013; 5:a012740.doi: 10.1101/cshperspect.a012740 [PubMed: 24097900]
23. Radhakrishnan SK, Jette N, Lees-Miller SP. Non-homologous end joining: Emerging themes and unanswered questions. *DNA Repair (Amst.).* 2014; 17:2–8. DOI: 10.1016/j.dnarep.2014.01.009 [PubMed: 24582502]
24. Chapman JR, Taylor MRG, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. *Mol Cell.* 2012; 47:497–510. DOI: 10.1016/j.molcel.2012.07.029 [PubMed: 22920291]
25. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. *Genes Dev.* 2011; 25:409–433. DOI: 10.1101/gad.2021311 [PubMed: 21363960]
26. Goodarzi, AA.; Jeggo, PA. The Repair and Signaling Responses to DNA Double-Strand Breaks. Elsevier; 2013. p. 1-45.
27. Panier S, Durocher D. Push back to respond better: regulatory inhibition of the DNA double-strand break response. *Nat Rev Mol Cell Biol.* 2013; 14:661–672. DOI: 10.1038/nrm3659 [PubMed: 24002223]
28. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. *Nat Cell Biol.* 2011; 13:1161–1169. DOI: 10.1038/ncb2344 [PubMed: 21968989]
29. McKinnon PJ. ATM and the Molecular Pathogenesis of Ataxia Telangiectasia. *Annu Rev Pathol Mech Dis.* 2012; 7:303–321. DOI: 10.1146/annurev-pathol-011811-132509
30. Stracker TH, Petrini JHJ. The MRE11 complex: starting from the ends. *Nat Rev Mol Cell Biol.* 2011; 12:90–103. DOI: 10.1038/nrm3047 [PubMed: 21252998]
31. Paull TT, Deshpande RA. The Mre11/Rad50/Nbs1 complex: Recent insights into catalytic activities and ATP-driven conformational changes. *Experimental Cell Research.* 2014; 329:139–147. DOI: 10.1016/j.yexcr.2014.07.007 [PubMed: 25016281]
32. Involvement of novel autophosphorylation sites in ATM activation. 2006; 25:3504–3514. DOI: 10.1038/sj.emboj.7601231
33. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. 2003; 421:499–506. DOI: 10.1038/nature01368
34. Sun, Y.; Xu, Y.; Roy, K.; Price, BD. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. 2007. <http://mcb.asm.org/content/27/24/8502.short>
35. Kaidi A, Jackson SP. KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling. *Nature.* 2013; 498:70–74. DOI: 10.1038/nature12201 [PubMed: 23708966]
36. Bensimon A, Schmidt A, Ziv Y, Elkon R, Wang SY, Chen DJ, et al. ATM-Dependent and -Independent Dynamics of the Nuclear Phosphoproteome After DNA Damage. *Science Signaling.* 2010; 3:rs3–rs3. DOI: 10.1126/scisignal.2001034 [PubMed: 21139141]

37. Mu JJ, Wang Y, Luo H, Leng M, Zhang J, Yang T, et al. A Proteomic Analysis of Ataxia Telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) Substrates Identifies the Ubiquitin-Proteasome System as a Regulator for DNA Damage Checkpoints. *J Biol Chem*. 2007; 282:17330–17334. DOI: 10.1074/jbc.C700079200 [PubMed: 17478428]
38. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science*. 2007; 316:1160–1166. [PubMed: 17525332]
39. Bensimon A, Aebersold R, Shiloh Y. Beyond ATM: The protein kinase landscape of the DNA damage response. *FEBS Letters*. 2011; 585:1625–1639. DOI: 10.1016/j.febslet.2011.05.013 [PubMed: 21570395]
40. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. *Nucleic Acids Research*. 2007; 35:7475–7484. DOI: 10.1093/nar/gkm744 [PubMed: 17942417]
41. Velimezi G, Lontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M, et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. *Nat Cell Biol*. 2013; 15:967–977. DOI: 10.1038/ncb2795 [PubMed: 23851489]
42. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. *Embo J*. 2005; 24:1157–1169. DOI: 10.1038/sj.emboj.7600608 [PubMed: 15775976]
43. Shiloh Y. ATM (ataxia telangiectasia mutated): expanding roles in the DNA damage response and cellular homeostasis. *Biochem Soc Trans*. 2001; 29:661. doi: 10.1042/0300-5127:0290661 [PubMed: 11709050]
44. Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. *Trends in Biochemical Sciences*. 2012; 37:15–22. DOI: 10.1016/j.tibs.2011.10.002 [PubMed: 22079189]
45. Xu B, Boohaker R. The versatile functions of ATM kinase. *Biomed J*. 2014; 37:3. doi: 10.4103/2319-4170.125655 [PubMed: 24667671]
46. Semlitsch M, Shackelford RE, Zirkel S, Sattler W, Malle E. ATM protects against oxidative stress induced by oxidized low-density lipoprotein. *DNA Repair (Amst)*. 2011; 10:848–860. DOI: 10.1016/j.dnarep.2011.05.004 [PubMed: 21669554]
47. Espach Y, Lochner A, Strijdom H, Huisamen B. ATM Protein Kinase Signaling, Type 2 Diabetes and Cardiovascular Disease. *Cardiovasc Drugs Ther*. 2015; 29:51–58. DOI: 10.1007/s10557-015-6571-z [PubMed: 25687661]
48. Takagi M, Uno H, Nishi R, Sugimoto M, Hasegawa S, Piao J, et al. ATM Regulates Adipocyte Differentiation and Contributes to Glucose Homeostasis. *CellReports*. 2015; doi: 10.1016/j.celrep.2015.01.027
49. Valentin-Vega YA, MacLean KH, Tait-Mulder J, Milasta S, Steeves M, Dorsey FC, et al. Mitochondrial dysfunction in ataxia-telangiectasia. *Blood*. 2012; 119:1490–1500. DOI: 10.1182/blood-2011-08-373639 [PubMed: 22144182]
50. Zhang J, Tripathi DN, Jing J, Alexander A, Kim J, Powell RT, et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. *Nat Cell Biol*. 2015; 17:1259–1269. DOI: 10.1038/ncb3230 [PubMed: 26344566]
51. Sharma NK, Lebedeva M, Thomas T, Kovalenko OA, Stumpf JD, Shadel GS, et al. Intrinsic mitochondrial DNA repair defects in Ataxia Telangiectasia. *DNA Repair (Amst)*. 2014; 13:22–31. DOI: 10.1016/j.dnarep.2013.11.002 [PubMed: 24342190]
52. Bareti D, Williams RL. PIKKs — the solenoid nest where partners and kinases meet. *Curr Opin Struct Biol*. 2014; 29:134–142. DOI: 10.1016/j.sbi.2014.11.003 [PubMed: 25460276]
53. Lovejoy CA, Cortez D. Common mechanisms of PIKK regulation. *DNA Repair (Amst)*. 2009; 8:1004–1008. DOI: 10.1016/j.dnarep.2009.04.006 [PubMed: 19464237]
54. Chen BPC, Li M, Asaithamby A. New insights into the roles of ATM and DNA-PKcs in the cellular response to oxidative stress. *Cancer Letters*. 2012; 327:103–110. DOI: 10.1016/j.canlet.2011.12.004 [PubMed: 22155347]
55. Kong X, Shen Y, Jiang N, Fei X, Mi J. Emerging roles of DNA-PK besides DNA repair. *Cellular Signalling*. 2011; 23:1273–1280. DOI: 10.1016/j.cellsig.2011.04.005 [PubMed: 21514376]

56. Errico A, Costanzo V. Mechanisms of replication fork protection: a safeguard for genome stability. *Crit Rev Biochem Mol Biol.* 2012; 47:222–235. DOI: 10.3109/10409238.2012.655374 [PubMed: 22324461]
57. Gobbin E, Cesena D, Galbiati A, Lockhart A, Longhese MP. Interplays between ATM/Tel1 and ATR/Mec1 in sensing and signaling DNA double-strand breaks. *DNA Repair (Amst.).* 2013; 12:791–799. DOI: 10.1016/j.dnarep.2013.07.009 [PubMed: 23953933]
58. Shiloh Y. Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. *Annu Rev Genet.* 1997; 31:635–662. [PubMed: 9442910]
59. Perlman, SL.; Boder, E., deceased; Sedgewick, RP.; Gatti, RA. Ataxia–telangiectasia. *Ataxic Disorders.* Elsevier; 2012. p. 307–332.
60. Chrzanowska KH, Gregorek H, Dembowska-Bagi ska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). *Orphanet J Rare Dis.* 2012; 7:13.doi: 10.1186/1750-1172-7-13 [PubMed: 22373003]
61. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. *Nat Rev Cancer.* 2003; 3:23–34. DOI: 10.1038/nrc970 [PubMed: 12509764]
62. McKinnon PJ. Maintaining genome stability in the nervous system. *Nat Neurosci.* 2013; 16:1523–1529. DOI: 10.1038/nn.3537 [PubMed: 24165679]
63. Croteau DL. Human RecQ helicases in DNA repair, recombination, and replication. *Annu Rev Biochem.* 2014; 83:519–552. DOI: 10.1146/annurev-biochem-060713-035428 [PubMed: 24606147]
64. Ramirez CL, Cadinanos J, Varela I, Freije JM, Lopez-Otin C. Human progeroid syndromes, aging and cancer: new genetic and epigenetic insights into old questions. *Cell Mol Life Sci.* 2007; 64:155–170. [PubMed: 17131053]
65. Shimizu I, Yoshida Y, Suda M, Minamino T. DNA Damage Response and Metabolic Disease. *Cell Metabolism.* 2014; 20:967–977. DOI: 10.1016/j.cmet.2014.10.008 [PubMed: 25456739]
66. Valentin-Vega YA, Kastan MB. A new role for ATM: regulating mitochondrial function and mitophagy. *Autophagy.* 2012; 8:840–841. DOI: 10.4161/auto.19693 [PubMed: 22617444]
67. Wu D. Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. *The Journal of Lipid Research.* 2005; 46:1380–1387. DOI: 10.1194/jlr.M400430-JLR200 [PubMed: 15863839]
68. Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. *Cell Metabolism.* 2006; 4:377–389. DOI: 10.1016/j.cmet.2006.10.002 [PubMed: 17084711]
69. Mercer JR, Cheng KK, Figg N, Gorenne I, Mahmoudi M, Griffin J, et al. DNA Damage Links Mitochondrial Dysfunction to Atherosclerosis and the Metabolic Syndrome. *Circulation Research.* 2010; 107:1021–1031. DOI: 10.1161/CIRCRESAHA.110.218966 [PubMed: 20705925]
70. Lane DP. Cancer. p53, guardian of the genome. *Nature.* 1992; 358:15–16. DOI: 10.1038/358015a0 [PubMed: 1614522]
71. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, et al. Modulation of mammalian life span by the short isoform of p53. *Genes Dev.* 2004; 18:306–319. [PubMed: 14871929]
72. Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. *Blood.* 2007; 109:1736–1742. DOI: 10.1182/blood-2006-03-010413 [PubMed: 17032926]
73. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. *Embo J.* 2002; 21:6225–6235. [PubMed: 12426394]
74. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, et al. Delayed ageing through damage protection by the Arf/p53 pathway. *Nature.* 2007; 448:375–379. DOI: 10.1038/nature05949 [PubMed: 17637672]
75. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. *Cell.* 2006; 127:1323–1334. DOI: 10.1016/j.cell.2006.12.007 [PubMed: 17182091]
76. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature.* 2007; 445:656–660. DOI: 10.1038/nature05529 [PubMed: 17251933]

77. Campisi J. 21: Cancer and ageing: Rival demons? 2014; 50:S6–S7. DOI: 10.1016/S0959-8049(14)50021-4
78. Burgess RC, Misteli T, Oberdoerffer P. DNA damage, chromatin, and transcription: the trinity of aging. *Curr Opin Cell Biol.* 2012; 24:724–730. DOI: 10.1016/j.ceb.2012.07.005 [PubMed: 22902297]
79. Karakasilioti I, Kamileri I, Chatzinikolaou G, Kosteas T, Vergadi E, Robinson AR, et al. DNA Damage Triggers a Chronic Autoinflammatory Response, Leading to Fat Depletion in NER Progeria. *Cell Metabolism.* 2013; 18:403–415. DOI: 10.1016/j.cmet.2013.08.011 [PubMed: 24011075]
80. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* 2013; 153:1194–1217. DOI: 10.1016/j.cell.2013.05.039 [PubMed: 23746838]
81. Shadyab AH, LaCroix AZ. Genetic factors associated with longevity: A review of recent findings. *Ageing Res Rev.* 2015; 19:1–7. DOI: 10.1016/j.arr.2014.10.005 [PubMed: 25446805]
82. Wolters S, Schumacher B. Genome maintenance and transcription integrity in aging and disease. *Front Genet.* 2013; 4:19.doi: 10.3389/fgene.2013.00019 [PubMed: 23443494]
83. Vijg J, Suh Y. Genome instability and aging. *Annu Rev Physiol.* 2013; 75:645–668. DOI: 10.1146/annurev-physiol-030212-183715 [PubMed: 23398157]
84. Cleaver JE, Lam ET, Revet I. Disorders of nucleotide excision repair: the genetic and molecular basis of heterogeneity. *Nat Rev Genet.* 2009; 10:756–768. DOI: 10.1038/nrg2663 [PubMed: 19809470]
85. Vermeij WP, Hoeijmakers JH, Pothof J. Aging: not all DNA damage is equal. *Current Opinion in Genetics & Development.* 2014; 26:124–130. DOI: 10.1016/j.gde.2014.06.006 [PubMed: 25222498]
86. Gregg SQ, Robinson AR, Niedernhofer LJ. Physiological consequences of defects in ERCC1–XPF DNA repair endonuclease. *DNA Repair (Amst.).* 2011; 10:781–791. DOI: 10.1016/j.dnarep.2011.04.026 [PubMed: 21612988]
87. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA. 2014; 31:722–733. DOI: 10.1016/j.devcel.2014.11.012
88. van Deursen JM. The role of senescent cells in ageing. *Nature.* 2014; 509:439–446. DOI: 10.1038/nature13193 [PubMed: 24848057]
89. Velarde MC, Demaria M, Campisi J. Senescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy. *Cancer and Aging.* 2013; 38:17–27. DOI: 10.1159/000343572
90. Campisi J. Aging, cellular senescence, and cancer. *Annu Rev Physiol.* 2013; 75:685–705. DOI: 10.1146/annurev-physiol-030212-183653 [PubMed: 23140366]
91. Muñoz-Espín D, Serrano M. Cellular senescence: from physiology to pathology. *Nat Rev Mol Cell Biol.* 2014; 15:482–496. DOI: 10.1038/nrm3823 [PubMed: 24954210]
92. Campisi J, Robert L. Cell senescence: role in aging and age-related diseases. *Interdiscip Top Gerontol.* 2014; 39:45–61. DOI: 10.1159/000358899 [PubMed: 24862014]
93. Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. *Nat Rev Cancer.* 2015; 15:509–509. DOI: 10.1038/nrc3988
94. de Jesus BB, Blasco MA. Assessing Cell and Organ Senescence Biomarkers. *Circulation Research.* 2012; 111:97–109. DOI: 10.1161/CIRCRESAHA.111.247866 [PubMed: 22723221]
95. Campisi J. Cellular senescence: putting the paradoxes in perspective. *Current Opinion in Genetics & Development.* 2011; 21:107–112. DOI: 10.1016/j.gde.2010.10.005 [PubMed: 21093253]
96. Baker DJ, Wijshake T, Tchkonja T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature.* 2011; 479:232–236. DOI: 10.1038/nature10600 [PubMed: 22048312]
97. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: Linking Aging to Chronic Disease. *Cell.* 2014; 159:709–713. DOI: 10.1016/j.cell.2014.10.039 [PubMed: 25417146]
98. Zhu Y, Tchkonja T, Pirtskhalava T, Gower AC, Ding H, Giorgadze N, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. *Aging Cell.* 2015; 14:644–658. DOI: 10.1111/accel.12344 [PubMed: 25754370]

99. Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. *Nat Genet.* 2004; 36:744–749. DOI: 10.1038/ng1382 [PubMed: 15208629]
100. Baker DJ, Perez-Terzic C, Jin F, Pitel KS, Pitel K, Niederländer NJ, et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. *Nat Cell Biol.* 2008; 10:825–836. DOI: 10.1038/ncb1744 [PubMed: 18516091]
101. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. *Proceedings of the National Academy of Sciences of the United States of America.* 2001; 98:12072–12077. DOI: 10.1073/pnas.211053698 [PubMed: 11593017]
102. Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. *Cancer Res.* 2007; 67:3117–3126. DOI: 10.1158/0008-5472.CAN-06-3452 [PubMed: 17409418]
103. Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. *J Cell Sci.* 2010; 124:68–81. DOI: 10.1242/jcs.071340 [PubMed: 21118958]
104. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. *Nat Cell Biol.* 2009; 11:973–979. DOI: 10.1038/ncb1909 [PubMed: 19597488]
105. Vijg J, Campisi J. Puzzles, promises and a cure for ageing. *Nature.* 2008; 454:1065–1071. DOI: 10.1038/nature07216 [PubMed: 18756247]
106. Maslov AY, Ganapathi S, Westerhof M, Quispe W, White RR, Van Houten B, et al. DNA damage in normally and prematurely aged mice. *Aging Cell.* 2013; doi: 10.1111/ace1.12071
107. Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. *Cell.* 2013; 155:1119–1130. DOI: 10.1016/j.cell.2013.10.041 [PubMed: 24238961]
108. Muñoz-Espín D, Cañamero M, Maraver A, Gómez-López G, Contreras J, Murillo-Cuesta S, et al. Programmed Cell Senescence during Mammalian Embryonic Development. *Cell.* 2013; 155:1104–1118. DOI: 10.1016/j.cell.2013.10.019 [PubMed: 24238962]
109. Guo S, DiPietro LA. Factors Affecting Wound Healing. *Journal of Dental Research.* 2010; 89:219–229. DOI: 10.1177/0022034509359125 [PubMed: 20139336]
110. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of Activated Stellate Cells Limits Liver Fibrosis. *Cell.* 2008; 134:657–667. DOI: 10.1016/j.cell.2008.06.049 [PubMed: 18724938]
111. Jun J-I, Lau LF. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. *Nat Cell Biol.* 2010; 12:676–685. DOI: 10.1038/ncb2070 [PubMed: 20526329]
112. Schumacher B, van der Pluijm I, Moorhouse MJ, Kostas T, Robinson AR, Suh Y, et al. Delayed and accelerated aging share common longevity assurance mechanisms. *PLoS Genet.* 2008; 4:e1000161. doi: 10.1371/journal.pgen.1000161 [PubMed: 18704162]
113. Miyamoto S. Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. *Cell Res.* 2010; 21:116–130. DOI: 10.1038/cr.2010.179 [PubMed: 21187855]
114. Osorio FG, Bárcena C, Soria-Valles C, Ramsay AJ, de Carlos F, Cobo J, et al. Nuclear lamina defects cause ATM-dependent NF-κB activation and link accelerated aging to a systemic inflammatory response. *Genes Dev.* 2012; 26:2311–2324. DOI: 10.1101/gad.197954.112 [PubMed: 23019125]
115. Tilstra JS, Robinson AR, Wang J, Gregg SQ, Clauson CL, Reay DP, et al. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. *J Clin Invest.* 2012; 122:2601–2612. DOI: 10.1172/JCI45785 [PubMed: 22706308]
116. Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. *Nat Rev Immunol.* 2006; 6:261–270. DOI: 10.1038/nri1804 [PubMed: 16498454]
117. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. *Nature.* 2005; 436:1186–1190. DOI: 10.1038/nature03884 [PubMed: 15995699]

118. Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF Family Transcription Factors in Immunity and Oncogenesis. *Annu Rev Immunol.* 2008; 26:535–584. DOI: 10.1146/annurev.immunol.26.021607.090400 [PubMed: 18303999]
119. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. *Oncogene.* 2002; 21:7776–7785. DOI: 10.1038/sj.onc.1205981 [PubMed: 12420214]
120. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature.* 2009; 461:788–792. DOI: 10.1038/nature08476 [PubMed: 19776740]
121. Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, et al. STING Recognition of Cytoplasmic DNA Instigates Cellular Defense. *Molecular Cell.* 2013; 50:5–15. DOI: 10.1016/j.molcel.2013.01.039 [PubMed: 23478444]
122. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science.* 2013; 339:786–791. DOI: 10.1126/science.1232458 [PubMed: 23258413]
123. Härtlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity. *Immunity.* 2015; 42:332–343. DOI: 10.1016/j.immuni.2015.01.012 [PubMed: 25692705]
124. Gorgoulis VG, Zacharatos P, Kotsinas A, Kletsas D, Mariatos G, Zoumpourlis V, et al. p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. *Embo J.* 2003; 22:1567–1578. DOI: 10.1093/emboj/cdg157 [PubMed: 12660163]
125. Kang C, Xu Q, Martin TD, Li MZ, Demaria M, Aron L, et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. *Science.* 2015; 349:aaa5612–aaa5612. DOI: 10.1126/science.aaa5612 [PubMed: 26404840]
126. Ermolaeva MA, Schumacher B. Systemic DNA damage responses: organismal adaptations to genome instability. *Trends Genet.* 2014; 30:95–102. DOI: 10.1016/j.tig.2013.12.001 [PubMed: 24439457]
127. Ermolaeva MA, Segref A, Dakhovnik A, Ou H-L, Schneider JI, Utermöhlen O, et al. DNA damage in germ cells induces an innate immune response that triggers systemic stress resistance. *Nature.* 2013; 501:416–420. DOI: 10.1038/nature12452 [PubMed: 23975097]
128. van de Ven M, Andressoo JO, Holcomb VB, von Lindern M, Jong WM, Zeeuw CI, et al. Adaptive Stress Response in Segmental Progeria Resembles Long-Lived Dwarfism and Calorie Restriction in Mice. *PLoS Genet.* 2006; 2:e192.doi: 10.1371/journal.pgen.0020192 [PubMed: 17173483]
129. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell.* 2006; 124:315–329. [PubMed: 16439206]
130. Kenyon CJ. The genetics of ageing. *Nature.* 2010; 467:622–622. DOI: 10.1038/nature09047
131. Carter CS, Ramsey MM, Sonntag WE. A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. *Trends Genet.* 2002; 18:295–301. [PubMed: 12044358]
132. Liang H, Masoro EJ, Nelson JF, Strong R, McMahan CA, Richardson A. Genetic mouse models of extended lifespan. *Exp Gerontol.* 2003; 38:1353–1364. [PubMed: 14698816]
133. Holzenberger M, Dupont J, Ducos B, Leneuve P, Géloën A, Even PC, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature.* 2003; 421:182–187. DOI: 10.1038/nature01298 [PubMed: 12483226]
134. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. *Science.* 2005; 309:1829–1833. [PubMed: 16123266]
135. Schumacher B, Garinis GA, Hoeijmakers JHJ. Age to survive: DNA damage and aging. *Trends Genet.* 2008; 24:77–85. DOI: 10.1016/j.tig.2007.11.004 [PubMed: 18192065]
136. Mariño G, Ugalde AP, Fernández AF, Osorio FG, Fueyo A, Freije JMP, et al. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. *Proceedings of the National Academy of Sciences of the United States of America.* 2010; 107:1105–1110. DOI: 10.1073/pnas.0910050107 [PubMed: 20033333]

- States of America. 2010; 107:16268–16273. DOI: 10.1073/pnas.1002696107 [PubMed: 20805469]
137. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. *Br J Cancer*. 2005; 92:2097–2101. DOI: 10.1038/sj.bjc.6602627 [PubMed: 15956962]
 138. Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. *J Gerontol a Biol Sci Med Sci*. 2003; 58:291–296. [PubMed: 12663691]
 139. Ikeno Y, Hubbard GB, Lee S, Cortez LA, Lew CM, Webb CR, et al. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. *J Gerontol a Biol Sci Med Sci*. 2009; 64:522–529. DOI: 10.1093/gerona/glp017 [PubMed: 19228785]
 140. Garinis GA, Uittenboogaard LM, Stachelscheid H, Fousteri M, van Ijcken W, Breit TM, et al. Persistent transcription-blocking DNA lesions trigger somatic growth attenuation associated with longevity. *Nat Cell Biol*. 2009; 11:604–615. DOI: 10.1038/ncb1866 [PubMed: 19363488]
 141. Mueller MM, Castells-Roca L, Babu V, Ermolaeva MA, Müller R-U, Frommolt P, et al. DAF-16/FOXO and EGL-27/GATA promote developmental growth in response to persistent somatic DNA damage. *Nat Cell Biol*. 2014; doi: 10.1038/ncb3071
 142. Johnson TE. Increased life-span of age-1 mutants in *Caenorhabditis elegans* and lower Gompertz rate of aging. *Science*. 1990; 249:908–912. [PubMed: 2392681]
 143. Edifizi D, Schumacher B. Genome Instability in Development and Aging: Insights from Nucleotide Excision Repair in Humans, Mice, and Worms. *Biomolecules*. 2015; 5:1855–1869. DOI: 10.3390/biom5031855 [PubMed: 26287260]
 144. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R. A *C. elegans* mutant that lives twice as long as wild type. *Nature*. 1993; 366:461–464. DOI: 10.1038/366461a0 [PubMed: 8247153]

Fig. 1. Examples of distinct DNA damage repair and response defects leading to genetic disorders in humans.

Various damage types including SSBs, bulky lesions, DSBs and ICLs require single strand break repair, nucleotide excision repair (NER), homologous and non-homologous end joining and interstrand crosslink repair, respectively. Defects in DNA damage response pathways lead to genome instability and consequently to complex syndromes characterized by tissue degeneration, cancer susceptibility, developmental defects, and premature aging.

Fig. 2. Systemic responses to DNA damage.

Various endogenous and exogenous genotoxic stressors damage the DNA. Cell-non-autonomous DNA damage responses, such as attenuation of Insulin-like signaling (IIS) and activation of innate immune responses result in consequences of DNA lesions beyond the genotoxically insulted cells. Attenuation of IIS leads to decreased growth as well as to enhanced tissue maintenance, which promotes survival of the aging organism. Innate immune responses can promote clearance of damaged cells, thus contributing to tissue repair and maintenance. However, chronic inflammation can severely damage tissues thus contributing to functional decline and tissue degeneration.